Hemophilia A

HemA · Rare Disease · 9 drugs · 6 indications

Factor VIII deficiency causing bleeding disorder.
Competitive Landscape (9 drugs)
DrugCompanyMechanismModalityRouteStage
DenecimigNVO, GMABFVIIIa mimetic bispecific antibodyBispecific antibodySCFILED
NXT007ROG.SWFVIIIa mimetic bispecific antibodyBispecific antibodySCPHASE2
HemlibraROG.SWFVIIIa mimetic bispecific antibodyBispecificSCAPPROVED
AdynovateFactor VIII replacementProteinIVAPPROVED
AlhemoNVOAnti-TFPI (tissue factor pathway inhibitor) antibodyAntibodySCAPPROVED
HympavziAnti-TFPI (tissue factor pathway inhibitor) antibodyAntibodySCAPPROVED
FitusiranAnti-antithrombin siRNA (RNAi)siRNASCAPPROVED
AltuviiioSOBIExtended half-life recombinant Factor VIIIRecombinant proteinIVAPPROVED
EloctaSOBIRecombinant proteinIVAPPROVED
Indications (6)
Hemophilia A
NXT007 PHASE2Fitusiran APPROVEDDenecimig FILED
Hemophilia A with inhibitors
Hemlibra APPROVEDAlhemo APPROVED
Hemophilia A prophylaxis
Adynovate APPROVED
Hemophilia A without inhibitors
Hemlibra APPROVEDAlhemo APPROVEDHympavzi APPROVEDAltuviiio APPROVED
Hemophilia A with or without inhibitors
Hemophilia A, prophylaxis
Elocta APPROVED
Upcoming Catalysts
Altuviiio - Hemophilia A Commercial Ramp (EU/Middle East)COMMERCIAL
SOBIQuarterly through 2026-2027
Data from Supabase · Updated 2026-03-24